SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Luc Van Gaal, Elisabeth Souhami, Tianyue Zhou, Ronnie Aronson, Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus, Journal of Clinical & Translational Endocrinology, 2014, 1, 2, 31

    CrossRef

  2. 2
    Tatiana Dilla, Amparo Valladares, Claudia Nicolay, Javier Salvador, Jesús Reviriego, María Costi, Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain, Applied Health Economics and Health Policy, 2012, 10, 6, 417

    CrossRef

  3. 3
    Tatiana Dilla, Amparo Valladares, Claudia Nicolay, Javier Salvador, Jesús Reviriego, María Costi, Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain, Applied Health Economics and Health Policy, 2012, 10, 6, 417

    CrossRef

  4. 4
    Peter A. Hall, Geoffrey T. Fong, Alice Y. Cheng, Time perspective and weight management behaviors in newly diagnosed Type 2 diabetes: a mediational analysis, Journal of Behavioral Medicine, 2012, 35, 6, 569

    CrossRef

  5. 5
    N. M. McKeown, A. Hruby, E. Saltzman, S. Furlong Choumenkovitch, P. F. Jacques, Weighing in on Whole Grains: A Review of Evidence Linking Whole Grains to Body Weight, Cereal Foods World, 2012, 57, 1, 20

    CrossRef

  6. 6
    R. Tirado, A. Caixàs, Comparativa entre los diversos tratamientos de la hiperglucemia: estrategias para minimizar la ganancia ponderal en la diabetes tipo 2, Avances en Diabetología, 2010, 26, 3, 156

    CrossRef

  7. 7
    Elizabeth K. Hussey, Robert L. Dobbins, Randall R. Stoltz, Nancy L. Stockman, Robin L. O'Connor-Semmes, Anita Kapur, Sharon C. Murray, Debbi Layko, Derek J. R. Nunez, Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study, The Journal of Clinical Pharmacology, 2010, 50, 6
  8. 8
    Peter Kopelman, H. Gerrit Groot, Aila Rissanen, Stephan Rossner, Soren Toubro, Richard Palmer, Rob Hallam, Andrew Bryson, Roger I. Hickling, Weight Loss, HbA1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo-controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical), Obesity, 2010, 18, 1
  9. 9
    Amulya T. Siram, Robert Yanagisawa, Maria Skamagas, Weight Management in Type 2 Diabetes Mellitus, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2010, 77, 5
  10. 10
    T. Dilla, M. Costi, K.S. Boye, J. Reviriego, N. Yurgin, X. Badia, N. Lara-Suriñach, El impacto de la obesidad en el manejo y evolución de la diabetes mellitus, Revista Clínica Española, 2008, 208, 9, 437

    CrossRef

  11. 11
    E. Bonora, Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight, International Journal of Clinical Practice, 2007, 61,
  12. 12
    J. T. George, H. Dilworth, D. M. Matthews, E. A. McIntyre, G. A. McKay, Effect of a pocket-size tablet-dispensing device on glycaemic control in Type 2 diabetic patients, Diabetic Medicine, 2007, 24, 1
  13. 13
    Denise Joffe, Robert T. Yanagisawa, Metabolic Syndrome and Type 2 Diabetes: Can We Stop the Weight Gain with Diabetes?, Medical Clinics of North America, 2007, 91, 6, 1107

    CrossRef

  14. 14
    The Influence of Age on the Effects of Lifestyle Modification and Metformin in Prevention of Diabetes, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2006, 61, 10, 1075

    CrossRef

  15. 15
    Alfredo Halpern, Marcio C Mancini, Diabesity, Treatments in Endocrinology, 2005, 4, 2, 65

    CrossRef

  16. 16
    Jaime Arroyo, Xavier Badía, Hermenegildo de la Calle, Javier Díez, Enric Estmatjes, Isabel Fernández, Claudia Filozof, Josep Franch, Gemma Gambús, Ramón Gomis, Javier Navarro, Pedro de Pablos, Tratamiento de los pacientes con diabetes mellitus tipo 2 en atención primaria en España, Medicina Clínica, 2005, 125, 5, 166

    CrossRef

  17. 17
    Bret H Goodpaster, Donna Wolf, Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes, Pediatric Diabetes, 2004, 5, 4
  18. 18
    Andre J Scheen, Current Management Strategies for Coexisting Diabetes Mellitus and Obesity, Drugs, 2003, 63, 12, 1165

    CrossRef

  19. 19
    P. Dhindsa, A. R. Scott, R. Donnelly, Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year, Diabetic Medicine, 2003, 20, 4
  20. 20
    JoAnn Manson, Patrick Skerrett, Walter Willett, Handbook of Obesity, 2003,

    CrossRef

  21. 21
    M. Hanefeld, G. Sachse, The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial, Diabetes, Obesity and Metabolism, 2002, 4, 6
  22. 22
    Alison J. Evans, Andrew J. Krentz, Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes, Diabetes, Obesity and Metabolism, 2001, 3, 4
  23. 23
    Current Awareness, Diabetes/Metabolism Research and Reviews, 2000, 16, 6
  24. 24
    Lucie Nield, Helen Moore, Lee Hooper, Kennedy Cruickshank, Avni Vyas, Vicki Whittaker, Carolyn D Summerbell, Dietary advice for treatment of type 2 diabetes mellitus in adults, The Cochrane Library,
  25. 25
    Clifford J. Bailey, New Drugs for the Treatment of Diabetes Mellitus, International Textbook of Diabetes Mellitus,